232 related articles for article (PubMed ID: 27063622)
21. Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Kannel K; Alnek K; Vahter L; Gross-Paju K; Uibo R; Kisand KV
PLoS One; 2015; 10(11):e0143393. PubMed ID: 26600308
[TBL] [Abstract][Full Text] [Related]
22. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
Taupin P
Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
[TBL] [Abstract][Full Text] [Related]
23. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P
Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630
[TBL] [Abstract][Full Text] [Related]
24. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Intrathecal Free Light Chain Synthesis: Comparison of Different Quantitative Methods with the Detection of Oligoclonal Free Light Chains by Isoelectric Focusing and Affinity-Mediated Immunoblotting.
Zeman D; Kušnierová P; Švagera Z; Všianský F; Byrtusová M; Hradílek P; Kurková B; Zapletalová O; Bartoš V
PLoS One; 2016; 11(11):e0166556. PubMed ID: 27846293
[TBL] [Abstract][Full Text] [Related]
26. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.
Cross AH; Stark JL; Lauber J; Ramsbottom MJ; Lyons JA
J Neuroimmunol; 2006 Nov; 180(1-2):63-70. PubMed ID: 16904756
[TBL] [Abstract][Full Text] [Related]
27. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Monson NL; Cravens PD; Frohman EM; Hawker K; Racke MK
Arch Neurol; 2005 Feb; 62(2):258-64. PubMed ID: 15710854
[TBL] [Abstract][Full Text] [Related]
28. The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas.
Tesfa D; Sander B; Lindkvist H; Nilsson C; Kimby E; Hägglund H; Wahlin BE; Klimkowska M; Palmblad J
Med Oncol; 2021 May; 38(6):70. PubMed ID: 34003398
[TBL] [Abstract][Full Text] [Related]
29. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H
Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
[TBL] [Abstract][Full Text] [Related]
31. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
[TBL] [Abstract][Full Text] [Related]
32. CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes.
Gurtner KM; Shosha E; Bryant SC; Andreguetto BD; Murray DL; Pittock SJ; Willrich MAV
Clin Chem Lab Med; 2018 Jun; 56(7):1071-1080. PubMed ID: 29455184
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
[TBL] [Abstract][Full Text] [Related]
34. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
[TBL] [Abstract][Full Text] [Related]
35. The predictive value of CSF multiple assay in multiple sclerosis: A single center experience.
De Fino C; Lucchini M; Lucchetti D; Nociti V; Losavio FA; Bianco A; Colella F; Ricciardi-Tenore C; Sgambato A; Mirabella M
Mult Scler Relat Disord; 2019 Oct; 35():176-181. PubMed ID: 31394405
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis.
Hegen H; Milosavljevic D; Schnabl C; Manowiecka A; Walde J; Deisenhammer F; Presslauer S
Clin Chem Lab Med; 2018 Jul; 56(8):1383-1391. PubMed ID: 29648995
[TBL] [Abstract][Full Text] [Related]
37. Concentrations of immunoglobulin free light chains in cerebrospinal fluid predict increased level of brain atrophy in multiple sclerosis.
Nazarov V; Makshakov G; Kalinin I; Lapin S; Surkova E; Mikhailova L; Gilburd B; Skoromets A; Evdoshenko E
Immunol Res; 2018 Dec; 66(6):761-767. PubMed ID: 30635824
[TBL] [Abstract][Full Text] [Related]
38. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
[TBL] [Abstract][Full Text] [Related]
39. BAFF serum and CSF levels in patients with multiple sclerosis and infectious nervous system diseases.
Braun T; Juenemann M; Dornes K; El-Shazly J; Schramm P; Bick-Ackerschott S; Kaps M; Gerriets T; Blaes F; Tschernatsch M
Int J Neurosci; 2021 Dec; 131(12):1231-1236. PubMed ID: 32602764
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis.
Giovannoni G
Mult Scler; 2011 Mar; 17(3):259-61. PubMed ID: 21362756
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
